» Articles » PMID: 33586675

Research Gaps in Medical Treatment of Transgender/nonbinary People

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2021 Feb 15
PMID 33586675
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

With the growing number of transgender and gender-nonbinary individuals who are becoming visible, it is clear that there is a need to develop a rigorous evidence base to inform care practice. Transgender health research is often limited to HIV/AIDS or mental health research and is typically subsumed in larger studies with general LGBTQ focus. Although the number of knowledgeable health care providers remains modest, the model for the medical approach to transgender health is shifting owing to growing social awareness and an appreciation of a biological component. Gender-affirming medicine facilitates aligning the body of the transgender person with the gender identity; typical treatment regimens include hormone therapy and/or surgical interventions. While broadly safe, hormone treatments require some monitoring for safety. Exogenous estrogens are associated with a dose-dependent increase in venous thromboembolic risk, and androgens stimulate erythropoiesis. The degree to which progressing gender-affirming hormone treatment changes cancer risk, cardiac heart disease risk, and/or bone health remains unknown. Guidelines referencing the potential exacerbation of cancer, heart disease, or other disease risk often rely on physiology models, because conclusive clinical data do not exist. Dedicated research infrastructure and funding are needed to address the knowledge gap in the field.

Citing Articles

Exploring the role of sex hormones and gender diversity in multiple sclerosis.

Nesbitt C, van der Walt A, Butzkueven H, Cheung A, Jokubaitis V Nat Rev Neurol. 2024; 21(1):48-62.

PMID: 39658653 DOI: 10.1038/s41582-024-01042-x.


Breast care considerations for transgender and gender-diverse patients.

Carroll E, Rogers C, Summerside M, Cortina C Womens Health (Lond). 2024; 20:17455057241289706.

PMID: 39382481 PMC: 11465296. DOI: 10.1177/17455057241289706.


The Impact of a Breast Cancer Risk Assessment on the Decision for Gender-Affirming Chest Masculinization Surgery in Transgender and Gender-Diverse Individuals: A Pilot Single-Arm Educational Intervention Trial.

Cortina C, Purdy A, Brazauskas R, Stachowiak S, Fodrocy J, Klement K Ann Surg Oncol. 2024; 31(11):7474-7482.

PMID: 38940898 PMC: 11452287. DOI: 10.1245/s10434-024-15701-2.


Risk assessment of transgender people: implementation of a demasculinizing-feminizing rodent model including the evaluation of thyroid homeostasis.

Tammaro A, Lori G, Martinelli A, Cancemi L, Tassinari R, Maranghi F Biol Direct. 2024; 19(1):5.

PMID: 38166984 PMC: 10759629. DOI: 10.1186/s13062-023-00450-1.


Raising awareness of sex and gender bias in artificial intelligence and health.

Buslon N, Cortes A, Catuara-Solarz S, Cirillo D, Rementeria M Front Glob Womens Health. 2023; 4:970312.

PMID: 37746321 PMC: 10512182. DOI: 10.3389/fgwh.2023.970312.


References
1.
Somboonporn W, Davis S . Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev. 2004; 25(3):374-88. DOI: 10.1210/er.2003-0016. View

2.
Guss C, Williams D, Reisner S, Austin S, Katz-Wise S . Disordered Weight Management Behaviors, Nonprescription Steroid Use, and Weight Perception in Transgender Youth. J Adolesc Health. 2016; 60(1):17-22. PMC: 8091135. DOI: 10.1016/j.jadohealth.2016.08.027. View

3.
Feldman J, Swinburne Romine R, Bockting W . HIV risk behaviors in the U.S. transgender population: prevalence and predictors in a large internet sample. J Homosex. 2014; 61(11):1558-88. PMC: 4162812. DOI: 10.1080/00918369.2014.944048. View

4.
Asscheman H, Giltay E, Megens J, de Ronde W, van Trotsenburg M, Gooren L . A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011; 164(4):635-42. DOI: 10.1530/EJE-10-1038. View

5.
Manson J, Chlebowski R, Stefanick M, Aragaki A, Rossouw J, Prentice R . Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013; 310(13):1353-68. PMC: 3963523. DOI: 10.1001/jama.2013.278040. View